US Patent 8,513,299: Scope, Claim Construction, Expiration Risk, and Doxepin Patent Landscape

US Patent 8,513,299 protects a narrow method of using low-dose doxepin to improve sleep maintenance, particularly sleep that ends or becomes fragmented during the final hour of an intended eight-hour sleep period. The patent does not broadly claim doxepin, all insomnia treatment, or a doxepin formulation. Its commercial relevance is concentrated in low-dose doxepin products such as Silenor and generic products labeled for sleep-maintenance insomnia.

The strongest claim themes are:

Patient selection based on early awakening or fragmented sleep during hour eight.
Doxepin dosing between approximately 0.5 mg and 6 mg.
Treatment directed at extending sleep into the final portion of an eight-hour period.
Method-of-treatment protection rather than composition-of-matter protection.

The principal vulnerabilities are inherency, obviousness, claim construction, enablement, and infringement proof. Claims 1 and 22 require a specific clinical presentation. Claims 9 through 16 target fragmented sleep in the eighth hour. The patent does not prevent use of higher-dose doxepin for depression or anxiety, nor does it block every formulation containing doxepin.

What does US Patent 8,513,299 claim?

The patent has 22 claims, with three independent claims:

Claim	Independent or dependent	Core subject matter
1	Independent	Identifying early awakening during the final 60 minutes of an intended eight-hour sleep period and administering 0.5-6 mg doxepin
2-8	Dependent	Narrower awakening windows, sleep extension, wake-after-sleep reduction, and insomnia types
9	Independent	Treating fragmented sleep during the eighth hour with 0.5-6 mg doxepin
10-16	Dependent	Specific doses and chronic, non-chronic, or transient insomnia
17-21	Dependent	Specific doses under claim 1
22	Independent	Reducing early awakenings through patient identification and 0.5-6 mg doxepin

The patent is therefore a targeted method-of-use patent. It relies on a combination of patient phenotype, timing of sleep loss, dose, and intended therapeutic result.

How broad is the scope of claim 1?

Claim 1 contains five material limitations:

A method for reducing or preventing early awakenings.
A patient in need of treatment.
A sleep disorder in which desired sleep lasts eight hours but actual sleep ends during the final 60 minutes.
Administration of doxepin or a pharmaceutically acceptable salt.
A dose between approximately 0.5 mg and 6 mg that is effective to lengthen the sleep period.

The claim does not require a particular tablet, capsule, excipient, release profile, brand, manufacturer, or administration route. It can potentially read on any product that supplies doxepin within the claimed dose range and is used for the specified patient population.

The patient-selection limitation materially narrows the claim. A patient who has difficulty falling asleep but sleeps continuously after falling asleep may not satisfy the early-awakening limitation. A patient who awakens at hour six also falls outside the literal “final 60 minutes” limitation of an eight-hour period.

The phrase “about 0.5 and 6 mg” creates a claim-construction issue. “About” permits some tolerance around the stated endpoints, but the permitted range depends on the specification, prosecution history, dosage-form accuracy, and ordinary meaning in the pharmaceutical field. A product marketed at 6 mg is a clear target. Doses materially above 6 mg present a stronger noninfringement position, although the doctrine of equivalents could remain relevant.

What do claims 2 through 8 add?

Claims 2 and 3 narrow the awakening period:

Claim 2: awakening during the final 45 minutes.
Claim 3: awakening during the final 30 minutes.

Claims 4 and 5 narrow the therapeutic outcome:

Claim 4 requires sleep to terminate during the eighth hour.
Claim 5 requires sleep to extend beyond hour 7.5.

Claim 6 adds a patient identified as needing reduced wake time after sleep. Claims 7 and 8 specify chronic, non-chronic, and transient insomnia.

These claims provide fallback positions if the broader 60-minute or general sleep-extension language is rejected. Claims 4 and 5 are particularly important because they link the treatment to a measurable sleep-maintenance endpoint rather than merely the administration of doxepin.

What do claims 9 through 16 protect?

Claims 9 through 16 address fragmented sleep during the eighth hour. Claim 9 is independent and requires:

A patient suffering from fragmented sleep during hour eight; and
Administration of 0.5-6 mg doxepin or a pharmaceutically acceptable salt.

Claims 10 through 14 identify dose levels of approximately 0.5 mg, 1 mg, 3 mg, and 6 mg. Claims 15 and 16 specify chronic, non-chronic, and transient insomnia.

This claim group differs from claim 1 in an important way. Claim 1 centers on a sleep period that terminates early. Claim 9 centers on fragmentation during the eighth hour, even if the patient ultimately remains in bed or returns to sleep. A product used for sleep-maintenance insomnia could implicate either group depending on the diagnosis, label, clinical instructions, and evidence of use.

Are claims 10 and 11 internally consistent?

Claims 10 and 11 present a drafting weakness.

Claim 10 states that the dose is about 1 mg, 3 mg, or 6 mg. Claim 11 depends on claim 10 but states that the dose is about 0.5 mg. Under conventional claim-dependency rules, claim 11 includes all limitations of claim 10 plus the additional limitation in claim 11. That creates an apparent inconsistency because a dose cannot ordinarily be both approximately 0.5 mg and approximately 1 mg, 3 mg, or 6 mg.

Possible interpretations include:

Claim 11 contains a drafting error.
“Claim 10” was intended to refer to claim 9.
The court may construe claim 11 as an independent 0.5 mg fallback despite the dependency problem.
The claim may face an indefiniteness or invalid-dependency challenge.

This issue does not necessarily impair claims 1 or 22, but it weakens the 0.5 mg claim position.

How does claim 22 differ from claim 1?

Claim 22 is broader in one respect and narrower in another.

It is broader because it does not expressly require that the dose be “effective to lengthen the sleep period.” It requires identification of the early-awakening patient and provision of 0.5-6 mg doxepin.

It is narrower because it expressly recites “reducing early awakenings” as the method objective. The claim still requires the same patient-selection facts: an intended eight-hour sleep period and actual termination during the final 60 minutes.

For infringement purposes, claim 22 may be easier to assert where clinical records establish the patient profile and prescribed dose but do not establish a measured increase in total sleep time. For validity purposes, the absence of an express efficacy limitation may expose the claim to an argument that it covers administration without a demonstrated therapeutic result.

What type of patent protection does US 8,513,299 provide?

Protection category	Coverage under US 8,513,299
Active ingredient	No broad composition-of-matter protection for doxepin
Low-dose use	Yes
Early-awakening treatment	Yes
Sleep-maintenance insomnia	Yes, through specified method claims
Fragmented sleep in hour eight	Yes
Specific doses	Yes, principally 0.5, 1, 3, and 6 mg
Formulation	No express formulation limitation in the supplied claims
Manufacturing process	No
Salt forms	Yes, to the extent they are pharmaceutically acceptable doxepin salts
Route of administration	No express route limitation
Patient phenotype	Yes
Broad psychiatric uses of doxepin	No

The patent is not a formulation patent on its face. A separate patent could protect tablet composition, dissolution, particle size, coating, excipients, or manufacturing controls. Those rights must be analyzed independently from the supplied claims.

What patents protect low-dose doxepin products?

Low-dose doxepin products generally require analysis across four patent categories:

Method-of-use patents

US 8,513,299 is principally in this category. It covers selected sleep-maintenance patients and specified dosing.

Formulation patents

A formulation patent may cover a 3 mg or 6 mg tablet, dosage uniformity, dissolution characteristics, excipient combinations, or stability. Such claims can create infringement risk even where a generic avoids the method claims.

Regulatory-use patents

A patent listed in the FDA Orange Book may identify an approved method of use for the reference product. A generic applicant can challenge listed patents through a Paragraph IV certification or may carve out the patented indication under a section viii statement, subject to FDA requirements.

Manufacturing patents

These may cover synthesis, purification, salt formation, crystallization, granulation, compression, or quality-control methods. They usually create greater supplier-side risk than direct product-label risk.

US 8,513,299, based on the supplied claims, should not be treated as proof that all of these categories are covered. Its text supports method-of-use coverage only.

When does US 8,513,299 lose exclusivity?

The patent’s enforceable expiration date cannot be derived from the claims alone. Patent term depends on the relevant nonprovisional filing date, priority chain, patent-term adjustment, terminal disclaimers, patent-term extension, and any disclaimer or correction recorded in the USPTO patent file. Patent number 8,513,299 indicates issuance in 2013, but issuance date is not the expiration date.

The governing baseline is generally 20 years from the earliest effective US nonprovisional filing date for applications subject to the post-1995 patent-term regime, with adjustments under 35 U.S.C. §§ 154 and 156. A reliable exclusivity analysis must distinguish:

Patent expiration.
FDA regulatory exclusivity.
Orange Book listing.
Pediatric exclusivity.
Enforceability after post-grant proceedings.
Any terminal disclaimer tying the patent to another patent.

The FDA’s Orange Book is the relevant source for listed patents and exclusivity associated with an approved drug. The USPTO patent file is the relevant source for term adjustment, disclaimers, reexamination, and post-grant events [2, 3].

What is the Orange Book status of low-dose doxepin?

Silenor is the principal branded low-dose doxepin reference product associated with sleep-maintenance insomnia. FDA-approved strengths include 3 mg and 6 mg tablets. The FDA labeling describes use for insomnia characterized by difficulty with sleep maintenance and instructs administration near bedtime [4].

For generic entry, an ANDA applicant must address each Orange Book-listed patent through one of four principal certifications:

Certification	Effect
Paragraph I	No patent information is listed
Paragraph II	Listed patent has expired
Paragraph III	Applicant will wait until patent expiration
Paragraph IV	Listed patent is invalid, unenforceable, or not infringed

A generic applicant may also use a section viii statement for a patented method that it does not seek to market. Whether a carve-out is feasible depends on the wording of the approved labeling and whether the remaining label still encourages the patented use.

What Paragraph IV risks apply to doxepin generics?

The principal Paragraph IV arguments against claims of this type would be:

Noninfringement

A generic could argue that its label does not identify:

Early awakening during the final 60 minutes.
Fragmented sleep during hour eight.
The claimed patient phenotype.
Treatment intended to extend sleep into the eighth hour.

A label that simply states “difficulty with sleep maintenance” may or may not induce infringement, depending on the full label, prescribing information, promotional conduct, and the scope of the approved indication.

Anticipation

Prior art could defeat the claims if it disclosed low-dose doxepin for insomnia and the claimed patient profile, dose, and sleep endpoint in a single reference. General disclosure of doxepin for insomnia would not necessarily anticipate the specific eighth-hour phenotype.

Obviousness

Obviousness is the more substantial validity risk. A challenger could combine:

Prior clinical use of doxepin for insomnia.
Known low-dose antihistaminic or H1-antagonist activity.
Sleep-maintenance endpoints.
Standard eight-hour polysomnography or sleep-diary measurements.
A motivation to avoid next-day sedation associated with higher doses.

The patent holder would respond that the claimed dose range and final-hour patient selection produced a clinically distinct effect that was not predictable from conventional doxepin use.

Written description and enablement

The specification must support the full dose range, patient subgroups, and claimed outcomes. A narrow clinical dataset may support 3 mg and 6 mg but provide weaker support for 0.5 mg or every patient within the broad 0.5-6 mg range.

How strong is the patent estate?

The supplied patent has moderate commercial value but limited blocking breadth.

Factor	Assessment
Claim breadth	Moderate to narrow
Product relevance	High for 3 mg and 6 mg low-dose doxepin
Composition protection	None apparent
Formulation protection	None apparent from supplied claims
Label-induced infringement risk	Material
Design-around potential	Meaningful
Obviousness exposure	Material
Patient-selection specificity	Provides differentiation but narrows enforcement
Biosimilar relevance	None
Generic relevance	High

The claims are strongest when a reference product label or promotional material expressly identifies sleep-maintenance insomnia, early awakening, or fragmented sleep late in the sleep period and supplies 3 mg or 6 mg doxepin. They are weaker against a generic label that omits the eighth-hour language and relies on a legally permissible indication carve-out.

What generic launch scenarios exist?

At-risk launch before patent expiration

A generic applicant could launch after receiving FDA approval but before resolution of patent litigation, accepting potential damages and injunction risk. This approach is commercially aggressive and depends on the perceived strength of the Paragraph IV case.

Launch after litigation settlement

The parties may agree to an authorized-generic arrangement, a delayed generic entry date, a license, or a settlement conditioned on regulatory and antitrust review. No settlement terms should be inferred from the patent claims alone.

Label carve-out

A generic may remove the patented method from its label if the remaining labeling does not encourage the patented use. This strategy is less effective where the patented method substantially overlaps the core approved indication.

Noninfringing formulation or dosage strategy

A product outside the claimed dose range may reduce literal infringement risk. A dose materially above 6 mg, a different indication, or a formulation used for a non-sleep disorder may avoid these claims, although separate patents and induced-infringement theories remain relevant.

Does biosimilar risk apply?

No. Doxepin is a small-molecule active ingredient. FDA competition proceeds through the ANDA pathway, not the biosimilar pathway under the Public Health Service Act. The relevant issues are therapeutic equivalence, patent certification, labeling, formulation, and generic substitution.

What litigation affects US 8,513,299?

A complete litigation assessment requires the USPTO patent file, FDA Orange Book records, PACER or CourtListener docket information, and Federal Circuit decisions. The supplied claims alone establish no litigation outcome, settlement, injunction, or final validity determination.

The key litigation questions are:

Whether the patent is listed for the reference drug.
Whether an ANDA applicant filed a Paragraph IV certification.
Whether the patent owner sued within the 45-day statutory period.
Whether a 30-month stay applied.
Whether the parties settled.
Whether the patent survived validity and enforceability challenges.
Whether any later court decision narrowed the claim construction.

Patent status should not be inferred solely from the fact that the patent issued or from commercial availability of generic doxepin.

Key Takeaways

US 8,513,299 is a method-of-use patent for low-dose doxepin in sleep-maintenance disorders.
Its central limitation is the patient’s early awakening or fragmented sleep during the final hour of an intended eight-hour sleep period.
The principal commercial doses are 3 mg and 6 mg, with additional claim coverage for 0.5 mg and 1 mg.
The patent does not broadly cover doxepin, all doxepin formulations, or all insomnia treatment.
Claims 1 and 22 address early awakening; claim 9 addresses fragmented sleep during hour eight.
Claim 11 has an apparent dependency inconsistency because it depends on a claim reciting 1, 3, or 6 mg but adds a 0.5 mg limitation.
The principal generic defenses are noninfringement, label carve-out, obviousness, anticipation, and lack of enablement or written description.
Biosimilar competition is irrelevant; ANDA-based generic competition is the applicable pathway.
Exact patent expiration and current litigation status require the USPTO and FDA records, not the claim text alone.

FAQs

Can a generic doxepin product avoid US 8,513,299 by using only 6 mg?

No. Six milligrams is expressly within the claimed range and is separately recited in dependent claims. Dose alone does not provide a design-around.

Does the patent cover doxepin for depression?

Not based on the supplied claims. The claims are directed to sleep disorders, early awakening, fragmented sleep, and low-dose administration. Higher-dose psychiatric treatment generally falls outside the claimed method, subject to the actual prescribing facts.

Can a 10 mg doxepin product infringe US 8,513,299?

Literal infringement is less likely because the claims recite approximately 0.5-6 mg. The doctrine of equivalents, prosecution history, and any separate patents would require independent analysis.

Does a prescription for “insomnia” automatically infringe the patent?

No. Infringement depends on the patient characteristics, dose, intended use, label language, physician instructions, and evidence showing that the patented method is being practiced or induced.

Is a formulation patent required to block generic entry?

No. A valid method-of-use patent can create an entry barrier if the generic label induces the patented use. A formulation patent is a separate and potentially cumulative barrier.

References

United States Patent No. 8,513,299, claims 1-22.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation under 35 U.S.C. § 154.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
U.S. Food and Drug Administration. (2010). Silenor (doxepin) tablets prescribing information.
United States Code, 35 U.S.C. §§ 101, 102, 103, 112, 154, and 271.
United States Code, 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-001	Mar 17, 2010	AB	RX	Yes	No	8,513,299	⤷ Start Trial				TREATMENT OF INSOMNIA	⤷ Start Trial
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-002	Mar 17, 2010	AB	RX	Yes	Yes	8,513,299	⤷ Start Trial				TREATMENT OF INSOMNIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2687118	⤷ Start Trial
Canada	2687124	⤷ Start Trial
European Patent Office	2026792	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,513,299